Intestinal Failure clinical trials

Explore recruiting intestinal failure clinical trials.

Recruiting intestinal failure studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Intestinal Failure trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2b/3 Randomized Open-Label Dose-Selection Study with Open-Label Extension and Randomized Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Safety and Efficacy of Choline Chloride for Injection (Low Dose and High Dose) Versus Placebo in Adolescents and Adults with Intestinal Failure Receiving Long-Term Parenteral Support

France, Denmark, Germany, Belgium, Poland

Phase II and Phase III (Integrated) EU CTIS Study details

A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 in Adult Subjects with Short Bowel Syndrome-associated Intestinal Failure (SBS-IF) (DOLPHINS-2)

France, Germany, Poland, Denmark, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of adult patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF) without colon in continuity (CIC)

Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orziloben (NST-6179) in Subjects with Intestinal Failure-Associated Liver Disease (IFALD)

Belgium, Denmark, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice-Weekly, Followed by a Long-Term, Open-Label Safety Evaluation in Patients with Short Bowel Syndrome–Intestinal Failure (SBS-IF)

Finland, France, Belgium, Germany, Hungary, Spain +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Intestinal Failure trials by city

Intestinal Failure in Toronto Intestinal Failure in Vancouver Intestinal Failure in Montreal Intestinal Failure in Calgary Intestinal Failure in Edmonton Intestinal Failure in Ottawa Intestinal Failure in Winnipeg Intestinal Failure in Quebec City Intestinal Failure in Hamilton Intestinal Failure in Kitchener Intestinal Failure in London Intestinal Failure in Halifax Intestinal Failure in New York Intestinal Failure in Los Angeles Intestinal Failure in Chicago Intestinal Failure in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease